Search Results - "Chavez Mac Gregor, M."

Use of bone-modifying agents (BMA) and osteonecrosis of the jaw (ONJ) among older patients with metastatic breast cancer (BC) by Chavez Mac Gregor, M., Lei, X., Zhao, H., van Poznak, C., Giordano, S.H.

Get full text

Oncotype Dx results in patients ≤40 years: Does age matter? New insights by Namuche, F., Ruiz, R.E., Morante Cruz, Z.D., Urrunaga, D., Ziegler, G., Mantilla, R., Leon Rivera, M., Chavez Mac Gregor, M., Gomez Moreno, H.L.

Get full text

Abstract SP027: Treatment differences and consequences by Chavez Mac Gregor, M

“…Breast cancer is the deadliest cancer among women worldwide, with a total of over half a million deaths annually impacting both developed and developing…”
Get full text

174P Breast cancer (BC) and severe COVID-19 (C-19) outcomes: A matched analysis by Chavez Mac Gregor, M., Lei, X., Zhao, H., Malinowski, C., Giordano, S.H.

Get full text

177P Health related quality of life in older breast cancer survivors by Giordano, S.H., Liao, K., Li, L., Zorzi, D., Holmes, H., Chavez Mac Gregor, M., Peterson, S.

Get full text

413P Characteristics of patients (pts) with previously treated, oestrogen receptor-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) who had rapid progression (RP) in acelERA BC by Martin Jimenez, M., Hilz, S., Collier, A., Chibly, A., Sohn, J., Bardia, A., Lim, E., Chavez Mac Gregor, M., Martinalbo, J., Pérez-Moreno, P.D., Moore, H.M.

Get full text

Determinants and outcomes associated with delays in adjuvant chemotherapy among breast cancer patients by Chavez Mac Gregor, M., Lei, X., Zhao, H., Giordano, S.H.

Get full text

Impact of delayed neoadjuvant systemic chemotherapy on survival among breast cancer patients by Gregor, M Chavez Mac, Lei, X., Gagliato, D., Valero, V., Barcenas, C., Hortobagyi, G.N., Giordano, S.H.

Get full text

210P - Impact of delayed neoadjuvant systemic chemotherapy on survival among breast cancer patients by Gregor, M Chavez Mac, Lei, X., Gagliato, D., Valero, V., Barcenas, C., Hortobagyi, G.N., Giordano, S.H.

“…Delays in the initiation of therapy among patients with early stage and locally advanced breast cancer (BC), can negatively impact survival. Patients treated…”
Get full text

349PUse of bone-modifying agents (BMA) and osteonecrosis of the jaw (ONJ) among older patients with metastatic breast cancer (BC) by Chavez Mac Gregor, M, Lei, X, Zhao, H, van Poznak, C, Giordano, S H

Get full text

210PImpact of delayed neoadjuvant systemic chemotherapy on survival among breast cancer patients by Gregor, M Chavez Mac, Lei, X, Gagliato, D, Valero, V, Barcenas, C, Hortobagyi, G N, Giordano, S H

“…Abstract Background Delays in the initiation of therapy among patients with early stage and locally advanced breast cancer (BC), can negatively impact…”
Get full text

Abstract P6-08-06: Association of body mass index (BMI) with chemotherapy administration and emergency room (ER) visits among breast cancer patients by Giordano, SH, Niu, J, Zhao, H, Zorzi, D, Chavez-Mac Gregor, M

“…Background: Obese patients may be more likely to have treatment-related complications. Little is known about the association between BMI and…”
Get full text

Abstract P3-08-18: Clinicopathological characteristics associated with intermediate and high-risk ODx RS by Ruiz, R, Morante, Z, Namuche, F, Urrunaga, D, Leon, M, Ziegler, G, Aguilar, A, Chavez Mac Gregor, M, Gomez, H

“…Background: The gene expression profiling assay OncotypeDx (ODx) prognosticates the risk of estrogen receptor positive (ER+) breast cancer (BC) recurrence and…”
Get full text

Abstract P3-08-16: Age's importance in early breast cancer: Oncotype Dx results in patients ≤40 years by Ruiz, R, Namuche, F, Morante, Z, Aguilar, A, Urrunaga, D, Ziegler, G, Chavez Mac Gregor, M, Leon, M, Gomez, H

“…Background The 21-gene recurrence score (RS) predicts the benefit of adjuvant chemotherapy (CT) in ER-positive HER2-negative breast cancer (BC) and has been…”
Get full text

211MO Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study by Martin Jimenez, M., Lim, E., Chavez Mac Gregor, M., Bardia, A., Wu, J., Zhang, Q., Nowecki, Z., Cruz, F., Safin, R., Kim, S-B., Schem, C., Montero, A., Khan, S., Bandyopadhyay, R., Shivhare, M., Patre, M., Martinalbo, J., Roncoroni, L., Pérez-Moreno, P.D., Sohn, J.

Get full text

Abstract P3-08-17: Evaluation of Oncotype DX testing and subsequent treatment choices in the Latin American setting by Ruiz, R, Morante, Z, Namuche, F, Urrunaga, D, Aguilar, A, Schwarz, J, Leon, M, Ziegler, G, Chavez Mac Gregor, M, Gomez, H

“…Background: The gene expression profiling assay OncotypeDx (ODx) prognosticates the risk of estrogen receptor positive (ER+) breast cancer (BC) recurrence and…”
Get full text

211POncotype Dx results in patients ≤40 years: Does age matter? New insights by Namuche, F, Ruiz, R E, Morante Cruz, Z D, Urrunaga, D, Ziegler, G, Mantilla, R, Leon Rivera, M, Chavez Mac Gregor, M, Gomez Moreno, H L

Get full text

Abstract P5-16-30: Feasibility trial for identification of patients for eliminating breast cancer surgery following neoadjuvant systemic therapy by Kuerer, HM, Rauch, GM, Krishnamurthy, S, Adrada, BE, Caudle, AS, DeSnyder, SM, Santiago, L, Lucci, A, Hobbs, BP, Gilcrease, M, Hwang, R, Candelaria, RP, Chavez Mac-Gregor, M, Arribas, E, Moseley, T, Teshome, M, Miggins, MV, Smith, BD, Valero, V, Hunt, KK, Yang, WT

“…Background: Contemporary improved neoadjuvant systemic therapy (NST) for breast cancer may result in a pathologic complete response (pCR) in up to 60% of…”
Get full text

Abstract P3-12-06: Statin use and outcome among breast cancer patients treated with neoadjuvant systemic chemotherapy by Chavez-Mac Gregor, M, Lei, X, Litton, JK, Melhem-Bertrand, A, Giordano, SH, Masuda, H, Ueno, N, Gabriel, HN, Valero, V

“…BACKGROUND: Statins are cholesterol-reducing agents that affect intracellular pathways associated with tumorigenesis and inflammation. Preclinical studies have…”
Get full text

Abstract P5-20-02: Predictors of long-term survival in a large cohort of patients with HER2-positive (HER2+) metastatic breast cancer (MBC) by Chavez, Mac Gregor M, Lei, X, Giordano, SH, Valero, V, Esteva, F, Mittendorf, EA, Gonzalez-Angulo, AM, Hortobagyi, GN

“…Background: Numerous studies have examined prognostic factors for survival in breast cancer patients (pts), but few have focused on long-term survival among…”
Get full text